SEC Form 4 · accession 0001140361-15-014235
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce Cousins
Officer — Exec VP & CFO
Period of report
Mar 30, 2015
Accepted (ET)
Apr 2, 2015 · 9:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $17.57 | Mar 30, 2015 | A | 80,000 | A | Mar 30, 2016 | Mar 30, 2025 | Common shares | 80,000 | 80,000 | D |
Explanation of responses
- F1The option vests in three equal installments beginning on the date so indicated and every 12 months thereafter, such grant vested in full at 3 years.